Session 2 - Miscellaneous Research
Sarah Allen - ADU CMN Patients with IVDU related infections and discharge against advice
Rachael Brooker - MERIT Lisdexamfetamine for acute methamphetamine withdrawal
Julie Humphreys - STP Psilocybin assisted psycho rx for methamphetamine use
Julie Carnell - DACS MNC Gambling in Australia during COVID-19
Stephen Weston - ACM Vaping
Fiona McDonald - STP / CC Performance and image enhancing drugs
Amanda Brown - Research Team Neuroimaging in addiction neuromodulation research
Marcia Nunes-Sequeira - DACS Med Eye movement desensitisation and reprocessing (EMDR)
Acheson LS, et al. One-third of people who inject drugs are at risk of incomplete treatment for staphylococcus aureus bacteraemia: a retrospective medical record review. Int J Infect Dis. 2021 Nov; 112: 63-65. PubMed PMID: 34520844
Acheson LS, et al. Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: a pilot feasibility and safety trial. Drug Alcohol Depend. 2022 Dec 1; 241: 109692. PubMed PMID: 36399936
Psilocybin-facilitated treatment for methamphetamine use disorder: a pilot study (Psi-MA)
Re-scheduling of psilocybin and MDMA in the Poisons Standard: questions and answers
Gambling in Australia during COVID-19
QuitNic: a pilot randomized controlled trial comparing nicotine vaping products with nicotine replacement therapy for smoking cessation following residential detoxification . Nicotine Tob Res. 2021 Feb 16; 23(3): 462-470. PubMed PMID: 32770246
GP guide to harm minimisation for patients using non-prescribed anabolic-androgenic steroids (AAS) and other performance and image enhancing drugs (PIEDs)